MTF Wound Care announces that its AmnioBand family of placental allografts and its AlloGraft Pliable tissue forms have received the American Podiatric Medical Association Seal of Approval (APMA).
AmnioBand, derived from dehydrated human placental tissue, is used as a scaffold for the treatment of chronic non-healing wounds such as diabetic foot ulcers, venous leg ulcers, and pressure ulcers.
AlloPatch Pliable is an acellular human dermal graft designed to support host tissue remodeling.
“Receiving the APMA Seal of Approval gives podiatrists and clinicians the confidence that AmnioBand and AlloPatch Pliable are beneficial in healing patients’ wounds,” says Kim Rounds, vice president, MTF Wound Care, in a media release.
“Placing our tissues through the APMA’s detailed evaluation demonstrates our commitment to be a partner of choice. We are proud of this notable accomplishment that recognizes the strength of our portfolio,” she adds.
The APMA Seal of Approval is granted to products that are beneficial to foot health. Companies must provide comprehensive information on each product: objective data from clinical and/or laboratory studies, intended use, patents, composition, and evidence of quality control. Each committee member conducts a detailed review, and a recommendation is then sent to the APMA Board of Trustees, which may either accept or reject the recommendation, the release explains.
Edison, NJ-based MTF Wound Care, a division of the Musculoskeletal Transplant Foundation, is a national consortium comprised of leading organ procurement organizations, tissue recovery organizations, and academic medical institutions, per the release.
[Source(s): MTF Wound Care, PR Newswire]
